Abstract
Our results indicate that INPP4B promotes leukemia cell survival via SGK3 activation, and INPP4B might be a potential target in the treatment of NPM1-mutated AML.
Introduction
Acute Myeloid Leukemia (AML) with mutated nucleophosmin (NPM1) is a distinct clinical entity, often associated with a normal karyotype but complex underlying genetics. While the PI3K signaling pathway is a known driver in many leukemias, the specific mechanisms sustaining cell survival in NPM1-mutated cases remain poorly understood.
The protein INPP4B (Inositol polyphosphate 4-phosphatase type II) acts as a "chameleon" in cancer biology; it functions as a tumor suppressor in breast and prostate cancers but has recently been linked to poor prognosis in AML. This research investigates how INPP4B functions in the context of NPM1 mutations and whether it bypasses traditional signaling routes to sustain leukemia cell survival.
Methods
The researchers employed a multi-disciplinary approach to map the INPP4B signaling axis:
- Expression Analysis: qRT-PCR and Western blotting were used to measure INPP4B levels in primary patient blasts and the NPM1-mutated OCI-AML3 cell line.
- Functional Assays: siRNA and lentiviral shRNA were used to knock down INPP4B, followed by CCK-8 and colony-forming assays to measure proliferation.
- Pathway Mapping: Specific inhibitors (PI3K, AKT, and mTOR) and rescue experiments were conducted to distinguish between SGK3 and AKT effectors.
- Lipid Analysis: ELISA quantified the mass of phosphoinositide signaling lipids, specifically PI(3,4)P₂ and PI(3)P.
- Bioinformatics: Clinical validation was performed using RNA-seq and clinical data from 171 AML patients in The Cancer Genome Atlas (TCGA).
Key Results
Differential Expression and Clinical Impact
INPP4B mRNA expression was found to be significantly higher in NPM1-mutated AML compared to non-mutated cases across both large-scale genomic datasets and local patient cohorts.
In the NPM1-mutated cohort, high INPP4B expression served as a biomarker for poor prognosis, correlating with a median overall survival of only 10.1 months, compared to 24.3 months for those with low expression (p = 0.04).
The SGK3 Survival Axis
Unlike many PI3K-driven cancers, INPP4B-mediated survival in NPM1-mutated AML is AKT-independent. Instead, it relies on SGK3 (serum and glucocorticoid-regulated kinase 3). INPP4B dephosphorylates PI(3,4)P₂ to produce PI(3)P, which recruits SGK3 to early endosomes for activation. This high level of INPP4B is driven by the NPM1 mutation itself through an ERK/Ets-1 signaling cascade.
Functional knockdown of INPP4B in OCI-AML3 cells led to a dramatic reduction in colony formation (approximately 60%) and cell viability. Re-introducing SGK3 into these depleted cells partially restored proliferation, confirming its role as the critical downstream mediator.
Conclusion
INPP4B acts as an oncogene in NPM1-mutated AML by activating the SGK3 pathway rather than the canonical AKT pathway. These findings identify the INPP4B/SGK3 axis as a potential new therapeutic target. Future work should focus on developing clinically viable small-molecule inhibitors for this pathway and validating these results in vivo using xenograft models.
Summary updated